Nxera Pharma Co., Ltd.
SOLTF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | -0.04 | 0.61 | 0.08 |
| FCF Yield | -3.59% | -0.31% | 0.63% | -12.77% |
| EV / EBITDA | -66.64 | 220.76 | -100.33 | -42.80 |
| Quality | ||||
| ROIC | -1.39% | -1.36% | -2.62% | -3.79% |
| Gross Margin | 60.42% | 78.01% | 75.69% | 68.96% |
| Cash Conversion Ratio | 1.78 | 0.08 | -0.81 | 8.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 21.04% | 26.94% | 26.10% | 22.81% |
| Free Cash Flow Growth | 92.29% | -153.57% | 104.53% | -856.67% |
| Safety | ||||
| Net Debt / EBITDA | -19.20 | 59.64 | -28.62 | -11.42 |
| Interest Coverage | -17.10 | -1.22 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.28 | 0.21 | 0.18 | 0.24 |
| Cash Conversion Cycle | 287.72 | 279.92 | 323.03 | 290.45 |